RBF Protein with MA103 Adjuvant Elicited Protective Immunity against Human Respiratory Syncytial Virus in BALB/c Mice-Reference-Cited by-同舟云学术

RBF Protein with MA103 Adjuvant Elicited Protective Immunity against Human Respiratory Syncytial Virus in BALB/c Mice

Published:2023-05-31 Issue:3 Volume:76 Page:183-190
ISSN:1344-6304
Container-title:Japanese Journal of Infectious Diseases
language:en
Short-container-title:Jpn J Infect Dis

Author:

Fang Qiongqiong¹,Li Hai²,Ren Hu²,Cao Lei²,Hu Hongqiao²,Zhang Yan²,Xu Wenbo²

Affiliation:

1. Beijing Centers for Disease Control and Preventative Medical Research, Beijing Center for Disease Prevention and Control, China

2. NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China

Publisher

Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

https://www.jstage.jst.go.jp/article/yoken/76/3/76_JJID.2022.476/_pdf

Reference31 articles.

1. 1. The Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394:757-779.

2. 2. Fleming DM, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15:443.

3. 3. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422-434.

4. 4. Waris ME, Tsou C, Erdman DD, et al. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol. 1996;70:2852-2860.

5. 5. Falsey AR, Walsh EE, Scott DA, et al. Phase 1/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine. J Infect Dis. 2022;225:2056-2066.